A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs

Nature Communications

Volumn 7, Issue , 2016, Pages

  Karlas, Alexander ^a,b   Berre, Stefano ^c,d   Couderc, Thérèse ^c,d   Varjak, Margus ^e   Braun, Peter ^a,b   Meyer, Michael ^b   Gangneux, Nicolas ^c,d   Karo Astover, Liis ^e   Weege, Friderike ^a   Raftery, Martin ^f   Schönrich, Günther ^f   Klemm, Uwe ^a   Wurzlbauer, Anne ^g   Bracher, Franz ^g   Merits, Andres ^e   Meyer, Thomas F ^a,b   Lecuit, Marc ^c,d,h  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b Steinbeis Innovation GGmbH   (Germany)

^c INSTITUT PASTEUR   (France)

^d INSERM   (France)

^e UNIVERSITY OF TARTU   (Estonia)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; 5 TETRADECYLOXY 2 FUROIC ACID; 6 HYDROXYFLAVONE; ACICLOVIR; ADENOSINE TRIPHOSPHATASE INHIBITOR; ALSTERPAULLONE; ANACARDIC ACID; ANNH 14; ANNH 18; ANTIVIRUS AGENT; AXITINIB; BAFILOMYCIN; CERULENIN; FELODIPINE; HOST FACTOR; KHCB 19; LINIFANIB; PAZOPANIB; PERPHENAZINE; PIMOZIDE; PRENYLAMINE; SMALL INTERFERING RNA; SORAFENIB; TETRAHYDROLIPSTATIN; TIVOZANIB; UNCLASSIFIED DRUG; 5-(TETRADECYLOXY)-2-FURANCARBOXYLIC ACID; FURAN DERIVATIVE;

DRUG; FATTY ACID; GENETIC ANALYSIS; GENOME; INFECTIVITY; INHIBITOR; TOXICITY; VACCINE; VIRUS;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOOD AND DRUG ADMINISTRATION; GENOME-WIDE ASSOCIATION STUDY; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN GENOME; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; MOLECULAR LIBRARY; PHARMACOLOGY; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ALPHAVIRUS; CHIKUNGUNYA VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; FURANS; GENE EXPRESSION PROFILING; GENOME, HUMAN; HEK293 CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; PIMOZIDE; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; VIRUS REPLICATION;

EID: 84968563019     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11320     Document Type: Article

References (50)

1. Weaver, S. C., Lecuit, M. Chikungunya virus and the global spread of a mosquito-borne disease. New Engl. J. Med. 372, 1231-1239 (2015).
2. Bekerman, E., Einav, S. Infectious disease. Combating emerging viral threats. Science 348, 282-283 (2015).
3. De Clercq, E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6, 1001-1018 (2007).
4. Scheel, T. K., Rice, C. M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19, 837-849 (2013).
5. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
6. Lin, K., Gallay, P. Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res. 99, 68-77 (2013).
7. Garcia, M. et al. Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci. Transl. Med. 4, 123-124 (2012).
8. Ashburn, T. T., Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673-683 (2004).
9. Karlas, A. et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463, 818-822 (2010).
10. Ooi, Y. S., Stiles, K. M., Liu, C. Y., Taylor, G. M., Kielian, M. Genome-wide RNAi screen identifies novel host proteins required for alphavirus entry. PLoS Pathog. 9, e1003835 (2013).
11. Panda, D. et al. Genome-wide RNAi screen identifies SEC61A and VCP as conserved regulators of Sindbis virus entry. Cell Rep. 5, 1737-1748 (2013).
12. Varble, A. et al. An in vivo RNAi screening approach to identify host determinants of virus replication. Cell Host Microbe 14, 346-356 (2013).
13. Brass, A. L. et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319, 921-926 (2008).
14. Konig, R. et al. Human host factors required for influenza virus replication. Nature 463, 813-817 (2010).
15. Boutros, M., Bras, L. P., Huber, W. Analysis of cell-based RNAi screens. Genome Biol. 7, R66 (2006).
16. Konig, R. et al. A probability-based approach for the analysis of large-scale RNAi screens. Nat. Methods 4, 847-849 (2007).
17. Zhang, X. D. et al. cSSMD: assessing collective activity for addressing off-target effects in genome-scale RNA interference screens. Bioinformatics 27, 2775-2781 (2011).
18. Tai, A. W. et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5, 298-307 (2009).
19. Li, Q. et al. Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle. PLoS Pathog. 10, e1004163 (2014).
20. Sessions, O. M. et al. Discovery of insect and human dengue virus host factors. Nature 458, 1047-1050 (2009).
21. Krishnan, M. N. et al. RNA interference screen for human genes associated with West Nile virus infection. Nature 455, 242-245 (2008).
22. Konig, R. et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135, 49-60 (2008).
23. Sivan, G. et al. Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. Proc. Natl Acad. Sci. USA 110, 3519-3524 (2013).
24. Heaton, N. S. et al. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc. Natl Acad. Sci. USA 107, 17345-17350 (2010).
25. Munger, J. et al. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat. Biotechnol. 26, 1179-1186 (2008).
26. Varjak, M. et al. Magnetic fractionation and proteomic dissection of cellular organelles occupied by the late replication complexes of Semliki Forest virus. J. Virol. 87, 10295-10312 (2013).
27. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-D1097 (2014).
28. Davis, M. I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051 (2011).
29. Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107 (2012).
30. Sourisseau, M. et al. Characterization of reemerging chikungunya virus. PLoS Pathog. 3, e89 (2007).
31. Yasunaga, A. et al. Genome-wide RNAi screen identifies broadly-acting host factors that inhibit arbovirus infection. PLoS Pathog. 10, e1003914 2014Þ.
32. Couderc, T. et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signalling are risk factors for severe disease. PLoS Pathog. 4, e29 (2008).
33. Bhargava, P., Robinson, M. O. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr. Oncol. Rep. 13, 103-111 (2011).
34. Nelson, E. A. et al. The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations. Genes Cancer 3, 503-511 (2012).
35. Kang, S., Roh, Y. J., Kim, I. B. Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice. Exp. Eye Res. 112, 125-133 2013Þ.
36. Ziegler, S. A. et al. In vivo imaging of chikungunya virus in mice and Aedes mosquitoes using a Renilla luciferase clone. Vector Borne Zoonotic Dis. 11, 1471-1477 (2011).
37. Morrison, T. E. et al. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am. J. Pathol. 178, 32-40 (2011).
38. Teo, T. H. et al. A pathogenic role for CD4\+ T cells during Chikungunya virus infection in mice. J. Immunol. 190, 259-269 (2013).
39. Vanlandingham, D. L. et al. Development and characterization of a double subgenomic chikungunya virus infectious clone to express heterologous genes in Aedes aegypti mosquitoes. Insect Biochem. Mol. Biol. 35, 1162-1170 (2005).
40. Couderc, T. et al. Prophylaxis and therapy for Chikungunya virus infection. J. Infect. Dis. 200, 516-523 (2009).
41. Glasker, S. et al. Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout. Virol. J. 10, 235 (2013).
42. Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G., Webster, R. G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl Acad. Sci. USA 97, 6108-6113 (2000).
43. Hopkins, A. L., Groom, C. R. The druggable genome. Nat.Rev.Drug Discov. 1, 727-730 (2002).
44. Sanjana, N. E., Shalem, O., Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783-784 (2014).
45. Ritz, C. S., Streibig, J. C. Bioassay analysis using R. J. Statist. Software 12, 1-22 (2005).
46. Ponce, M. A., Erra-Balsells, R. Synthesis and isolation of bromo-betacarbolines obtained by bromination of beta-carboline alkaloids. J. Heterocyclic Chem. 38, 1087-1096 (2001).
47. Li, H.-Y., Koike, K., Ohmoto, T. New alkaloids, picrasidines W, X and Y, from Picrasma quassioides and X-ray crystallographic analysis of picrasidine Q. Chem. Pharm. Bull. 41, 1807-1811 (1993).
48. Ponce, M. A., Tarzi, O. I., Erra-Balsells, R. Synthesis and isolation of chlorobeta-carbolines obtained by chlorination of beta-carboline alkaloids in solution and in solid state. J. Heterocyclic Chem. 40, 419-426 (2003).
49. Pohl, B., Luchterhandt, T., Bracher, F. Total syntheses of the chlorinated b-carboline alkaloids bauerine A, B, and C. Synth. Commun. 37, 1273-1280 (2007).
50. Krzywinski, M., Altman, N. Points of significance: two-factor designs. Nat. Methods 11, 1187-1188 (2014).